Novo Nordisk heads into its May 6 earnings report carrying the weight of its worst clinical setback in years: the February 23 announcement that CagriSema, its most advanced next-generation obesity drug, failed to demonstrate non-inferiority to Eli Lilly’s tirzepatide in the REDEFINE 4 head-to-head trial. The result sent the stock down nearly 16% in a single session, wiped out whatever recovery had been building since the company’s January guidance warning, and definitively widened the competitive gap in the market that Novo had hoped to close rather than expand.
The trial data showed CagriSema produced average weight loss of 23% over 84 weeks against 25.5% for Zepbound, a 2.5 percentage point gap in an open-label study involving 809 patients.
That difference sounds modest but carries disproportionate commercial weight: it is the difference between a drug that could credibly challenge the market leader and one that enters as a second-tier option at best, asking doctors and patients to choose it over a more effective and now familiar competitor. Analysts at Goldman Sachs subsequently cut their combined CagriSema peak sales estimates by approximately 65%, labelling NVO a “show-me story.” BMO Capital cut its price target to $36.
CEO Mike Doustdar pushed back on the most pessimistic interpretations, telling analysts directly: “To say it’s obsolete is quite belittling a fantastic drug, in all honesty.” He argued that CagriSema still delivers superior weight loss to anything currently on the market and that higher-dose formulations in development could materially improve its efficacy profile. The company filed for FDA approval of CagriSema in Q1 2026 based on its REDEFINE 1 and REDEFINE 2 pivotal trial results, with an FDA decision expected by late 2026. A higher-dose CagriSema trial is planned to initiate in the second half of 2026, and REDEFINE 11, exploring the drug’s full weight loss potential, will report data in the first half of 2027.
The stock is currently trading at approximately $40.52, near the lower end of its 52-week range of $35.12 to $81.44, having lost more than 43% of its value over the past year. On standard valuation metrics the numbers look compelling: a trailing price-to-earnings ratio of approximately 11.6 times against a five-year median of 35.4 times, a forward dividend yield of roughly 3.1%, and a market capitalisation around $210 billion against a pipeline that includes multiple regulatory decisions scheduled across the next 12 to 18 months. Whether those metrics represent genuine value or a value trap depends almost entirely on how investors assess the company’s ability to compete in a market where tirzepatide has structural momentum.
The May 6 earnings call will be the first full quarterly update since the CagriSema trial miss and will be scrutinised for how management addresses three specific questions. The first is guidance: the company’s existing 2026 outlook of negative 5% to negative 13% adjusted sales growth at constant exchange rates was set before the REDEFINE 4 result and management faces pressure to either hold or narrow that range.
The second is Wegovy pill uptake, which was running at approximately 50,000 weekly prescriptions as of late January. Sustained momentum in the oral format is the most credible near-term commercial offset to injectable market share losses to Lilly. The third is manufacturing capacity, with Novo having pledged to launch Wegovy HD in the United States in April 2026 and committed approximately DKK 55 billion in capital expenditure for the year.
Free cash flow guidance of DKK 35 to 45 billion for 2026 gives the company significant capital flexibility but also signals to investors that management is prioritising financial conservatism over aggressive pipeline acceleration at a moment when the company most needs to demonstrate it can outspend competitors into the next product cycle. Novo announced in February that it would cut US list prices on Wegovy and Ozempic by up to 50% starting January 2027, reducing monthly prices to $675 from approximately $1,350.
That decision removes near-term pricing upside from the equation entirely and frames the company’s recovery as dependent on volume growth rather than pricing power, a harder path in a market where Lilly is simultaneously growing its own volume at faster rates.
